PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 15604288-8 2004 Furthermore, 5-AZA-dCyd-treatment reduced to 6 folds the differential expression of MAGE-A3 between clones 5 and 14, which became recognized to a similar extent by T cells specific for a MAGE-A-encoded peptide. Decitabine 13-23 MAGE family member A3 Homo sapiens 84-91 23266925-2 2013 We report the outcome of the first patient treated in a phase 1 study for relapsed neuroblastoma, using the chemotherapy agent decitabine to upregulate cancer testis antigen expression, followed by a dendritic cell vaccine targeting the cancer testis antigens MAGE-A1, MAGE-A3, and NY-ESO-1. Decitabine 127-137 MAGE family member A3 Homo sapiens 269-276 21626030-5 2011 We have demonstrated that the expression of MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells following exposure to pharmacologic levels of the demethylating agent 5-aza-2"-deoxycytidine (decitabine, DAC). Decitabine 187-209 MAGE family member A3 Homo sapiens 53-60 21626030-5 2011 We have demonstrated that the expression of MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells following exposure to pharmacologic levels of the demethylating agent 5-aza-2"-deoxycytidine (decitabine, DAC). Decitabine 211-221 MAGE family member A3 Homo sapiens 53-60 21626030-5 2011 We have demonstrated that the expression of MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells following exposure to pharmacologic levels of the demethylating agent 5-aza-2"-deoxycytidine (decitabine, DAC). Decitabine 223-226 MAGE family member A3 Homo sapiens 53-60 21626030-6 2011 Expression of NY-ESO-1, MAGE-A1, or MAGE-A3 was induced in 10/10 neuroblastoma cell lines after 5 days of exposure to DAC. Decitabine 118-121 MAGE family member A3 Homo sapiens 36-43 19610063-9 2009 Furthermore, treatment of cells expressing low MAGE-3/6 mRNA with a demethylating agent, 5-aza-2"-deoxycytidine (DAC), increased the expression of MAGE-3/6 and CTL recognition. Decitabine 89-111 MAGE family member A3 Homo sapiens 47-53 19610063-9 2009 Furthermore, treatment of cells expressing low MAGE-3/6 mRNA with a demethylating agent, 5-aza-2"-deoxycytidine (DAC), increased the expression of MAGE-3/6 and CTL recognition. Decitabine 89-111 MAGE family member A3 Homo sapiens 147-153 19610063-9 2009 Furthermore, treatment of cells expressing low MAGE-3/6 mRNA with a demethylating agent, 5-aza-2"-deoxycytidine (DAC), increased the expression of MAGE-3/6 and CTL recognition. Decitabine 113-116 MAGE family member A3 Homo sapiens 47-53 19610063-9 2009 Furthermore, treatment of cells expressing low MAGE-3/6 mRNA with a demethylating agent, 5-aza-2"-deoxycytidine (DAC), increased the expression of MAGE-3/6 and CTL recognition. Decitabine 113-116 MAGE family member A3 Homo sapiens 147-153 11924907-6 2002 Furthermore, de novo expression of MAGE3 gene induced by the treatment of Mel 195 melanoma cells with the DNA hypomethylating agent 5-aza-2"-deoxycytidine was associated with a 6%-12% demethylation of selected cytosine-guanine dinucleotides in its promoter. Decitabine 132-154 MAGE family member A3 Homo sapiens 35-40 11924907-7 2002 Finally, 5-aza-2"-deoxycytidine induced a 16-fold increase of MAGE3 expression in Mel 313 melanoma cells expressing constitutively low levels of the antigen, but did not affect that of Mel 275 melanoma cells expressing high baseline levels of MAGE3. Decitabine 9-31 MAGE family member A3 Homo sapiens 62-67 12123095-6 2002 Treatment of MAGE-A expression-negative pancreatic tumor cells with the demethylating agent 5-aza-2"-deoxycytidine could activate MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4 and GAGE transcription suggesting silencing due to promoter methylation. Decitabine 92-114 MAGE family member A3 Homo sapiens 148-155 11216765-6 2001 RESULTS: Relative to untreated controls, MAGE-3 expression was enhanced 32-fold (range 3.9 to 110) by DAC alone (0.1 micromol/L x 72 h), 2.1-fold (0.4 to 4.2) by DP alone (25 ng/mL x 6h), and 57-fold (4.6 to 209) by sequential DAC/DP exposure. Decitabine 102-105 MAGE family member A3 Homo sapiens 41-47 11216765-6 2001 RESULTS: Relative to untreated controls, MAGE-3 expression was enhanced 32-fold (range 3.9 to 110) by DAC alone (0.1 micromol/L x 72 h), 2.1-fold (0.4 to 4.2) by DP alone (25 ng/mL x 6h), and 57-fold (4.6 to 209) by sequential DAC/DP exposure. Decitabine 227-230 MAGE family member A3 Homo sapiens 41-47 11216765-11 2001 CONCLUSIONS: Sequential DAC/DP treatment may be a novel strategy to simultaneously augment MAGE-3 expression and induce growth arrest in thoracic malignancies. Decitabine 24-27 MAGE family member A3 Homo sapiens 91-97 28337274-4 2017 Decitabine treatment significantly improved MAGE-A1, MAGE-A3, and SP17 expression in these cell lines and in MDS patients. Decitabine 0-10 MAGE family member A3 Homo sapiens 53-60 9209667-8 1997 Either MAGE-1 or -3 gene expressions were induced in 1 of 3 MAGE-1 negative breast cell lines or 1 of 3 MAGE-3 negative breast cell lines by the treatment with 5-aza-2"-deoxycytidine. Decitabine 160-182 MAGE family member A3 Homo sapiens 104-110 30797153-0 2019 Decitabine enhances tumor recognition by T cells through upregulating the MAGE-A3 expression in esophageal carcinoma. Decitabine 0-10 MAGE family member A3 Homo sapiens 74-81 30797153-10 2019 We observed an efficient increase in MAGE-A3 expression in tumor cells and tissues after the treatment of decitabine and the expression of MAGE-A3 was affected by DNA methylation. Decitabine 106-116 MAGE family member A3 Homo sapiens 37-44 28337274-5 2017 Decitabine-treated K562 and SKM-1 target cells with incrementally induced MAGE-A1, MAGE-A3, or SP17 levels up-regulated T lymphocyte function. Decitabine 0-10 MAGE family member A3 Homo sapiens 83-90 26883197-5 2016 Induction of NY-ESO-1 and MAGEA3/A6, were observed following decitabine. Decitabine 61-71 MAGE family member A3 Homo sapiens 26-32